Ana Aparicio, MD of MD Anderson Cancer Center discusses how the CHARTED and STAMPEDE trials impacted her treatment for patients with metastatic hormone sensitive prostate cancer at the 2017 Genitourinary Cancers Symposium (Annual Meeting GU) in Orlando, Florida.